RENEW
ReNew (the “Company”), among the largest clean energy companies globally, announced on Wednesday that it has completed construction of 1.94 GW of RE assets in FY24, taking the cumulative capacity set up by the company to over 10 GW. Accounting for assets sold, the Company’s revenue generating capacity stands at 9.52 GW as on March 31, 2024. The Company added 1,174 MW of solar and 768 MW of wind energy during FY24. This is one of the highest ever capacity additions of wind energy among all companies in India, in a single year.
In FY24, ReNew contributed approximately 10 percent of India’s total solar and wind energy generation. The Company has India’s largest wind portfolio of 4.7 GW, representing 10.5 percent of India’s total wind energy capacity. In 2023-24, ReNew won auctions to supply 4.8 GW (PPA) RE capacity, accounting for 10.1 percent of the total capacity for which tenders were concluded during the year. Looking ahead, this would enable the Company to double our RE asset portfolio to 20 GW by 2027/28.
ReNew has a deep presence across the country with over 150 renewable energy sites across 10 Indian states and employs more than 4,000 people. The Company is among the top ten renewable energy companies globally (ex-China), thanks to its balanced portfolio of solar and wind energy. It has also achieved backward integration through the manufacturing of solar modules and cells. ReNew’s B2B vertical has marquee customers such as Amazon, Microsoft, Toyota, Suzuki, Ultratech Cement and DCM Shriram.
ReNew’s expansion plans are driven by its strong fundamentals. As on December 31, 2023, the Company has a balance sheet size of around US$ 10.6 billion (~INR 88,600 crore), with strong visibility of funding for current and future projects.
Sumant Sinha, Founder, Chairperson and Chief Executive Officer of ReNew said, “I am incredibly proud of the work we have done to reach this milestone. ReNew continues to be at the heart of India's transformation as a clean energy leader and our ambitions now are even bigger. We will double the amount of clean energy we generate over the next few years, while continuing our work to be completely carbon neutral as a company by 2040.
“Prime Minister Narendra Modi has laid out a bold vision of trebling India’s renewable energy capacity by the end of the decade, and we are committed to ensuring that India becomes a global leader in clean energy.”
The Company's expansion of its operational capability comes as India targets to achieve 500 GW of non-fossil fuel energy capacity and reduce its projected carbon emissions by one billion tonnes by 2030.
Established in 2011, ReNew has been a trailblazer in India’s renewable energy industry. The Company started its operations with a 25 MW wind project in Gujarat and entered the solar energy space in 2014. ReNew became the first clean energy firm to cross operating capacity of 1 GW in 2016 and doubled it to 2 GW the very next year. In 2019, ReNew became the first Indian renewable energy company to achieve the 5 GW milestone. The Company was listed on Nasdaq in 2021 with an enterprise valuation of over US$8 billion. The Company’s total capacity then was over 6 GW. During FY 2023-24, ReNew added 1.94 GW in FY 2023-24, one of the largest capacity additions in a year.
The Company has been playing a significant role in greening the Indian economy over the past decade. With a capacity close to 10 GW, ReNew will generate 21 billion units of clean electricity - enough to power 5.9 million households, and avoid 17 million tonnes of CO2 emissions annually. During the past seven years, ReNew helped avoid around 72 million tonnes of carbon emissions.
As a responsible corporate citizen, ReNew works closely with communities to create a positive impact at the grassroot level, and has saved over 600 million litres of water through deployment of robotic cleaning on solar modules in the past three years. The Company’s social initiatives have benefitted more than 1 million people across India.
ReNew has also taken the lead in adopting Fourth Industrial Revolution technologies. The Company has deployed advanced analytics across its solar and wind portfolio to enhance asset performance by 35 percent.
ReNew has received significant international recognition for its work. This includes being named by MIT Technology Review in their 2023 global list of Top 15 Climate Tech Companies to Watch; being recognized twice by the World Economic Forum as part of their Global Lighthouse Network and being declared as an Energy Transition Changemaker at the UN’s COP28.
About ReNew:
ReNew is a leading decarbonization solutions Company listed on Nasdaq (Nasdaq: RNW, RNWWW). ReNew's clean energy portfolio of ~13.8 GWs on a gross basis as of December 31, 2023, is one of the largest globally. In addition to being a major independent power producer in India, we provide end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. For more information, visit renew.com and follow us on LinkedIn, Facebook, Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410793651/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release
Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
